The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
445
Administered SC
Administered SC
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Time frame: Baseline, Week 68
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 68
Change from Baseline in the WOMAC Physical Function Subscale Score
Time frame: Baseline, Week 68
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 68
Percent Change from Baseline in Total Cholesterol
Time frame: Baseline, Week 68
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 68
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 68
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 68
Change from Baseline in Diastolic Blood Pressure (DBP)
Time frame: Baseline, Week 68
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 68
Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
Time frame: Baseline, Week 68
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arizona Research Center
Phoenix, Arizona, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Suncoast Research Group
Miami, Florida, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
Elite Clinical Trials
Blackfoot, Idaho, United States
Northwestern University
Chicago, Illinois, United States
MedVadis Research Corporation
Waltham, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Clinvest Research LLC
Springfield, Missouri, United States
...and 39 more locations
Change from Baseline in Average Pain Intensity Numeric Rating Score (API-NRS) Score
Time frame: Baseline, Week 68
Change from Baseline in Worst Pain Intensity Numeric Rating Score (WPI-NRS) Score
Time frame: Baseline, Week 68